Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche - LARVOL DELTA

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor (ASH 2025) - P1/2, P3 | "Secondary endpoints include overall survival, PFS in patients with prior exposure to noncovalent BTK inhibitors by IRC, PFS by INV, overall response rate by IRC and INV, rate of partial response with lymphocytosis or higher by IRC and INV, duration of response by IRC and INV, time to next treatment, and safety/tolerability per National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Recruitment is ongoing."

Clinical • IO biomarker • P3 data • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Leukemia • Lymphoma • Prolymphocytic Leukemia • Richter's Syndrome • Small Lymphocytic Lymphoma

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR) (ASH 2025) - P1 | "Exploratory endpoints include duration of response, progression-free survival, and overall survival. Correlative analysis includes minimal residual disease testing on banked diagnostic tissue and CSF from different timepoints."

Clinical • P1 data • Surgery • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • CNS Disorders • CNS Lymphoma • CNS Tumor • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder (ASH 2025) - P1 | "In SOT recipients with PTLD who progress following risk-adapted rituximab and front-line chemoimmunotherapy, clinical outcomes are very poor. A maximum of 26 patients will be treated with subcutaneous epcoritamab utilizing a Fleming Two-Stage design with a one-sided error rate of 5% and 80% power to detect an objective response rate of 50% (null hypothesis 20% response rate). Exploratory objectives will evaluate the peripheral blood immunophenotype changes through the course of treatment with epcoritamab, describe the relationship of tumor microenvironment characteristics with clinical response to epcoritamab, characterize Epstein-barr virus (EBV) methylation alterations in EBV positive PTLDs treated with epcoritamab, and describe the relationship between metabolic tumor volume at time of epcoritamab initiation and disease response."

Clinical • P1 data • Post-transplantation • B Cell Lymphoma • Bone Marrow Transplantation • Epstein-Barr Virus Infections • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Solid Organ Transplantation • Transplantation

Trial in progress: A phase II, multicentre study to evaluate the efficacy and safety of birelentinib (DZD8586) combination therapy in diffuse large B-cell lymphoma (TAI-SHAN12) (ASH 2025) - P1/2 | "The study consists of three arms: Arm 1: Birelentinib + R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) for 6 cycles. Arm 2: Birelentinib + R-GemOx (rituximab, gemcitabine, oxaliplatin) for 8 cycles. Arm 3: Birelentinib + BR (rituximab, bendamustine) for 6 cycles...Pharmacokinetic analyses will be conducted as secondary objectives in both parts of the study. Patient enrollment for this study commenced in July 2025 and is currently ongoing."

Clinical • Combination therapy • P2 data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • BCL2

The holistic trial: A comprehensive evaluation of two second-line therapeutic approaches for immune thrombocytopenia (ITP) – a pragmatic randomized controlled trial (ASH 2025) - P3 | "This trial aims to determine which of the two most widely used second-line therapies, rituximab or TPO-RA (avatrombopag) offers the better outcome and should be selected first, and whether specific patient subgroups may benefit more from one approach than the other. Furthermore, we seek to acquire knowledge on patient's perspectives, incorporating their preferences and experiences in treatment decisions, especially in relation to HR QoL . Funding statement: The study is sponsored by Østfold Hospital, Norway and supported by a grant from the Norwegian Regional Health Authority and SOBI."

Clinical • Hematological Disorders • Hepatitis B • Hepatology • Immune Thrombocytopenic Purpura • Immunology • Infectious Disease • Inflammation • Thrombocytopenia • Thrombocytopenic Purpura

primary breast lymphoma: A 10-year retrospective case series on clinical features, diagnostic imaging, and outcomes from a diverse population treated at mount sinai medical center in miami beach (ASH 2025) - "PBL management included radiotherapy in 5 pts (2 pts with concomitant Rituximab and 1 with R-CHOP), and chemoimmunotherapy alone in 3 pts (1 Hyper-CVAD and 2 R-CHOP)...Two pts failed initial therapy: one experienced progression with secondary central nervous system involvement, and the other had refractory Richter's transformation from CLL (s/p multiple treatments including axicabtagene ciloleucel)...Our findings contribute to the limited literature on breast lymphoma and underscore the importance of tailored monitoring of Hispanic pts as well as breast cancer survivors. Larger multi-center studies are needed to confirm our findings."

Retrospective data • B Cell Lymphoma • Breast Cancer • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • HER2 Breast Cancer • HER2 Positive Breast Cancer • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Richter's Syndrome • Solid Tumor • Waldenstrom Macroglobulinemia • HER-2 • PGR

Safety and efficacy of ibrutinib as a first line agent for Mantle Cell Lymphoma : A systematic review and meta-analysis (ASH 2025) - "While standard first-line chemotherapy regimens include rituximab and bendamustine or cytarabine containing regimens, Bruton tyrosine kinase inhibitors (BTKis), such as ibrutinib and zanubrutinib, have demonstrated efficacy in relapsed or refractory MCL and are now being explored as frontline options. Notably, acalabrutinib in combination with bedamustine and rituximab has received FDA approval for treatment-naïve MCL patients who are ineligible for autologous hematopoietic stem cell transplantation (HSCT)...Conclusions Ibrutinib-based regimens demonstrate a high objective response rate and an acceptable safety profile when used as a first-line treatment for MCL. However, the substantial heterogeneity and potential publication bias is identified."

Retrospective data • Review • Atrial Fibrillation • Bone Marrow Transplantation • Cardiovascular • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

Real-world outcomes of HIV-associated lymphomas: A retrospective study at a single tertiary center in Saudi Arabia (ASH 2025) - "Rituximab was included in 16 cases (72%)...To our knowledge, this is the first study of its kind from the Middle East. Ongoing efforts are essential to refine treatment approaches and improve long term outcomes in this high-risk population."

Real-world • Real-world evidence • Retrospective data • Burkitt Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Primary Central Nervous System Lymphoma • Septic Shock • T Cell Non-Hodgkin Lymphoma • CD4

National practice patterns and preferences in the use of fixed-duration vs. treat-to-progression therapies for CLL (ASH 2025) - "In the R/R setting, fixed-duration preferences included venetoclax plus rituximab (39%) and venetoclax plus obinutuzumab (34%)...Among TTP strategies, first-line use of acalabrutinib (56%) and zanubrutinib (52%) was prominent in the survey, aligning with claims data that showed both agents as the most prescribed TTP therapies (28% each)... This data highlighted evolving practice patterns in the management of CLL and revealed variation in treatment preferences among academic and community-based clinicians and between survey and claims data. While adoption of genetic testing and newer therapeutic options appears high, clinicians face ongoing challenges in selecting and implementing appropriate regimens, particularly when balancing patient-centered factors with clinical efficacy and operational realities. Both fixed-duration and TTP strategies offer distinct advantages and limitations."

IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • IGH • TP53

Genetic predispositions in children with primary immunodeficiency and lymphoma: Experience from king hussein cancer center (ASH 2025) - "Most patients received reduced-intensity chemotherapy protocols due to their immunodeficiency, along with supportive therapy such as monthly intravenous immunoglobulin (IVIG), antimicrobial prophylaxis, and rituximab for Epstein-Barr virus reactivation... Survival for children with lymphoma and PID was worse than for immunocompetent patients. Our findings underscore the need to screen newly diagnosed pediatric lymphoma cases for underlying immunodeficiency (especially in consanguineous families or those with recurrent infections). Early identification enables tailored chemotherapy, infection prophylaxis, and timely transplantation to improve outcomes."

Clinical • IO biomarker • Ataxia • B Cell Lymphoma • Epstein-Barr Virus Infections • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Movement Disorders • Non-Hodgkin’s Lymphoma • Oncology • Primary Immunodeficiency • ATM • DCLRE1C • DOCK8 • IRF8 • PIK3CD • PLCG2 • RASGRP1 • TNFRSF9

Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data (ASH 2025) - "All patients received at least 3 cycles of Pola-based regimens, with the vast majority administered Pola-R-CHP, consisting of polatuzumab vedotin (1.8 mg/kg, intravenous [IV], day 1); rituximab (375 mg/m², IV day 1); cyclophosphamide (750 mg/m², IV, day 1); doxorubicin (50 mg/m², IV, day 1); and prednisone (100 mg,oral, days 1–5), repeated every 21 days. Conclusion Our findings indicate that Pola-based regimens exhibit high response rates and favorable safety profiles in newly diagnosed DLBCL patients with high-risk features in real world settings. Prospective studies with larger cohorts are needed to further validate these observations."

Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • CD5 • CD79B • TP53

Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review (ASH 2025) - P3 | "Introduction: The phase III POLARIX study (NCT03274492) demonstrated the superiority of Polatuzumab vedotin (Pola) combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) over R-CHOP, marking the first major advancement in over 20 years in first-line (1L) diffuse large B-cell lymphoma (DLBCL). This SLR analyzing currently available RWD addressing the safety and effectiveness of Pola-R-CHP for 1L DLBCL aligns with results from the POLARIX trial. Despite study and reporting heterogeneity, response rates and PFS are consistent, as are outcomes in patients older than 80 years, supporting the use of this regimen in patients with newly diagnosed DLBCL."

Clinical • Real-world • Real-world evidence • Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma

Vincristine-induced neuropathy: Long term follow-up of lymphoma survivors treated with CHOP or dose-adjusted EPOCH chemotherapy (ASH 2025) - "Introduction: The incidence of Vincristine-induced neuropathy (VIN) occurs in up to 70% of non Hodgkin Lymphoma (NHL) survivors treated with front-line lymphoma regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and infusional dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), administered with or without rituximab (R) (Su et al., 2025). Overall, neuropathy outcomes varied in our cohort. For most, CIPN20 scores were stable to improved between T3 and T4, yet 3 participants (mean age 68.7) reported persistent numbness and tingling in their feet and toes. Increasing age has been reported as a risk factor for development of chemotherapy induced neuropathy with one study reporting persistence of symptoms in the post-treatment phase (Bulls et al., 2019; Hershman et al., 2016)."

Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Pain

Outcomes of diffuse large B-cell lymphoma and high-grade B-cell lymphoma in elderly patients aged ≥ 80 years-old treated in first line therapy: An analysis of the bra-DLBCL multicenter, real-world registry, retrospective study (ASH 2025) - "The preferred regimen in these treatment naïve patients was R-mini-CHOP (63%), followed by R-CHOP (15%)...Although the primary cause of failure was disease relapse/progression, the non-relapse mortality rate was high (26%), even though R-mini-CHOP was the preferred treatment. In this population, some of these non-relapse-related deaths can be non-treatment related, but future studies should test less toxic, more targeted therapies in patients ≥ 80 years."

Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

Treatment patterns and outcomes of primary central nervous system lymphoma treated with high-dose methotrexate with or without autologous stem cell transplantation or whole brain radiation in the rea-world setting (ASH 2025) - "During induction, 59% received HDMTX+rituximab (R), 39% received HDMTX+R+additional (A) chemotherapy such as temozolomide (MTR) (15%) and cytarabine/thiotepa (MATRix) (15%)...Thiotepa (TT)/BCNU was used for conditioning in 8 patients, and TT/Busulfan/Cyclophosphamide in 1... HDMTX-based induction chemotherapy is effective in patients with PCNSL, even in those with delayed diagnosis or initiation of therapy. Although a minority of patients received consolidation with ASCT, it was associated with 100% progression-free survival."

B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Pulmonary Disease • Respiratory Diseases • Transplantation

Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status (ASH 2025) - "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) is a common regimen that is well-tolerated in older adults with other comorbidities, for whom treatment of DLBCL is challenging and has inferior outcomes...The most common 2L treatment regimens were rituximab, ifosfamide, carboplatin, plus etoposide in ASCT (n=41, 62.1%) and bendamustine plus rituximab (n=62, 18.6%) in non-ASCT treated groups...A higher percentage of patients in the non-ASCT treated group, specifically in the R-GemOx subgroup, were older with higher ECOG scores and inferior treatment related outcomes, including a minority alive at 2 years. These findings highlight a continuing unmet need for more effective, safer treatments for patients with R/R DLBCL ineligible for or unable to access ASCT or CAR-T."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

The association between neighbourhood walkability and diffuse large B-cell lymphoma: A population-based Study (ASH 2025) - "Adults (≥18 years) with primary or transformed DLBCL who received curative-intent, rituximab-containing chemotherapy from Jan 2005 to Dec 2021 were included...This suggests a potential association between the built environment, physical activity and DLBCL oncogenesis, however, an association was not observed between neighbourhood walkability and overall survival. Further studies will be directed at investigating associations between neighbourhood walkability and healthcare utilization in patients with DLBCL."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Genetic Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Obesity

Real-world outcomes of autologous CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A single-center experience (ASH 2025) - "Twenty-two patients (73.3%) received R-CHOP as first-line chemoimmunotherapy...Two patients (6.7%) had prior anti-CD19 therapy, five (16.7%) had bendamustine exposure, and all patients received prior anti-CD20 monoclonal antibody...The most commonly used CART product was axicabtagene ciloleucel (N=28, 93%)...Tocilizumab was administered in 19 patients (63.3%), with 13 (68.4%) requiring only one dose...All ICANS patients received steroids, and four (33.3%) received anakinra...These findings affirm the safety and efficacy of autologous CD19-directed CAR T-cell therapy in routine clinical practice at a medium-sized academic institution. Continued research with larger sample sizes and extended follow-up periods is warranted to validate these results further."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

Clinicopathologic and treatment influences on diffuse large B-cell lymphoma survival: A 10-year safety-net hospital experience (ASH 2025) - "This 10-year retrospective study at a public safety-net hospital identifies older age, high-risk IPI, and elevated CCI as significant predictors of poorer survival in DLBCL patients. Comorbidities frequently precluded more intensive therapies such as DA-EPOCH-R or R-CHOP, underscoring the need for personalized treatment strategies. Compared to SEER data, our cohort exhibits a higher prevalence of comorbidities (e.g., 67% with CCI ≥4 vs."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Palliative care

Evolving prognostic impact of B symptoms in non-Hodgkin lymphoma: A competing-risks analysis of SEER data, 2010–2019 (ASH 2025) - "However, the therapeutic landscape of NHL has shifted over the past decade, with routine use of anti-CD20 monoclonal antibodies (e.g., rituximab), intensified chemotherapy regimens, and improved supportive care... In this large, nationally representative NHL cohort, the adverse impact of B symptoms on survival has persisted but reduced over the past decade. This attenuation was consistent across multiple statistical approaches, including time-varying Cox models, competing-risks regression, RMST comparisons, and sensitivity analyses. The reduced prognostic burden may reflect improvements in systemic therappy, supportive care, and overall disease management."

Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Comparative analysis of severe infection risk and survival outcomes in DLBCL patients treated with CAR T-cell therapy versus standard chemoimmunotherapy: Insights from real-world data (ASH 2025) - "In this large real-world analysis of DLBCL patients from 2017 onward, CAR T-cell therapy was not associated with a higher risk of severe infection compared to standard R-CHOP/R-EPOCH chemoimmunotherapy; in fact, the CAR-T cohort experienced a slightly lower 1-year sepsis incidence. Importantly, one-year survival probability in patients with outcome sepsis was comparable between the matched CAR-T and R-CHOP/R-EPOCH groups. These findings highlight that, under contemporary practice conditions, CAR-T therapy's safety profile with respect to life-threatening infections is at least equivalent to (and possibly better than) traditional chemoimmunotherapy."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Chronic Kidney Disease • Diabetes • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Metabolic Disorders • Nephrology • Neutropenia • Non-Hodgkin’s Lymphoma • Renal Disease • Septic Shock

Test characteristics of end-of-treatment PET scans in diffuse large b-cell lymphoma in a population-level cohort (ASH 2025) - " We conducted a retrospective cohort study using population-level administrative health data of all patients in Ontario, Canada, ≥18 years old with DLBCL, who received frontline rituximab-based chemoimmunotherapy followed by PET within 16 weeks of last chemotherapy from October 2009-May 2021...Positive predictive value of EOT PET is suboptimal, and a substantial number of patients require follow up testing despite not ultimately relapsing. Waiting a longer time to PET (>6 weeks) results in slightly lower false positives, higher PPV and specificity, with slightly lower NPV and sensitivity."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States (ASH 2025) - "Treatment regimens were categorized into 7 mutually exclusive groups: bendamustine (B)-based chemotherapy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without cytarabine), Bruton tyrosine kinase inhibitors (BTKi; covalent: zanubrutinib, acalabrutinib, ibrutinib, and non-covalent: pirtobrutinib), bortezomib (bort)-based, venetoclax (ven)-based, intensive chemotherapy (high-dose cytarabine, HyperCVAD (hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone, etc.), and other regimens (CAR-T or others). However, chemotherapy and/or immunotherapy were associated with the highest HCRU while BTKi were associated with the lowest HCRU. Notably, more than half of patients previously treated with BTKi and anti-CD20 therapies were subsequently treated with another covalent BTKi or a non-covalent BTKi, while approximately one-third received chemotherapy and/or immunotherapy, further emphasizing the need for novel..."

Clinical • HEOR • Real-world • Real-world evidence • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

Impact of primary CNS prophylaxis in high CNS-IPI DLBCL: Analysis from the czech national lymphoma registry (ASH 2025) - P=N/A | "As conventional chemotherapeutics used in 1st line treatment do not effectively cross the blood-brain barrier, prophylactic methotrexate (MTX) or cytarabine (AraC) can be added intravenously or directly as intrathecal injection to selected patients (pts) based on risk factors...In total, 1196 pts with DLBCL diagnosed between 2010 and 2021 and treated initially with R-CHOP, either at the Charles University General Hospital in Prague or the University Hospital Brno, were included, of which 338 had low (0-1), 528 intermediate (2-3), and 330 high (>3) CNS-IPI, respectively...These data are consistent with a growing body of evidence suggesting that IV CNS prophylaxis may be an ineffective practice in 1st line DLBCL treatment, but prospective studies are needed to confirm this hypothesis. Supported by grants: NU23-03-00127 and NU21-03-00411"

B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors (ASH 2025) - "All 4 DLBCL patients received R-CHOP or R-CHOP-like regimens as 1L therapy, while the MCL patient received bendamustine and rituximab (BR) as 1L therapy. Consolidation therapy with CAR-T following 1L treatment demonstrated encouraging rates of CMR, PFS, and OS in B-cell lymphoma patients with high risk of relapse. Administration of PD-1 inhibitors and/or IL-2 post-infusion may support sustained expansion and persistence of CAR-T cells. The safety profile was manageable: all CRS were mild, and no ICANS were observed, providing a valuable insight for CAR-T consolidation following 1L treatment."

Clinical • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Hepatology • Large B Cell Lymphoma • Leukopenia • Liver Failure • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Thrombocytopenia • IL2